CARsgen Therapeutics Corporation will soon be investing in its first North American biomanufacturing location in Right to Work Durham, North Carolina. In order to make this possible, they are investing $157 million toward the project. This will also allow the medical company access to some of the most sought-after medical researchers in Research Triangle Park. In fact, they plan to create 200 new jobs in the area. This will help CARsgen Therapeutics find treatments for cancer, as well as help further the economy.
From Area Development Magazine:
“We are very excited to receive the JDIG grant approval from the State of North Carolina. […] CARsgen will continuously develop and embed innovations to advance the revolutionary CAR-T cell therapy for unmet clinical needs. The company has launched clinical studies of our leading CT053 and CT041 CAR-T cell therapies in the United States. The new facilities will expand our global cGMP manufacturing capacity to produce the innovative CAR-T cell products for the U.S. patients.” […]
“Global companies know that North Carolina is a world class leader in biotechnology. […] Our state’s skilled workers, educational institutions and business environment provide life science companies with the tools they need to succeed.” […]
“It’s exciting to see a company at the cutting-edge of science join our growing biotech industry cluster. […] From companies exploring gene therapies to the innovative work CARsgen is conducting with immune-oncology, there’s no question that North Carolina will continue to play an important role in the future of this industry and the many lives of those impacted by the life sciences sector.”AREA DEVELOPMENT MAGAZINE
To read more updates on Right to Work states, click here.